UNASSIGNED: β2-agonists, inhaled corticosteroids (ICS), and leukotriene modulators are the most commonly used to treat asthma, and major genetic variations associated with differential response to these three drugs were identified via candidate gene association analysis, genome-wide association study (GWAS), and RNA sequencing.
UNASSIGNED: Genomics focuses on the effects of genetic variations in a group of genes. Most current studies have focused on the effect of single gene polymorphisms on drug efficacy, but the pharmacogenomics of asthma is inherently complex, with each factor having a small effect on drug responsiveness, and no single locus has yet been able to predict the variability in drug responsiveness.
UNASSIGNED: According to epidemiological researches, a worldwide increase in the prevalence of bronchial asthma over the past four decades was shown. Genomic approaches can be used to screen for genetic variants associated with drug response. Stratifying patients prior to treatment helps to optimize drug selection, maximize the effectiveness of individual treatment, and improve clinical outcomes.
未经批准:β2-激动剂,吸入性皮质类固醇(ICS),白三烯调节剂最常用于治疗哮喘,通过候选基因关联分析确定了与对这三种药物的差异反应相关的主要遗传变异,全基因组关联研究(GWAS),和RNA测序。
UNASSIGNED:基因组学专注于一组基因中遗传变异的影响。目前大多数研究集中在单基因多态性对药物疗效的影响,但是哮喘的药物基因组学本质上是复杂的,每个因素对药物反应性的影响都很小,并且还没有单个基因座能够预测药物反应性的变异性。
未经授权:根据流行病学研究,研究显示,在过去40年中,支气管哮喘的患病率在全球范围内有所增加.基因组方法可用于筛选与药物反应相关的遗传变体。在治疗前对患者进行分层有助于优化药物选择,最大限度地提高个体治疗的有效性,改善临床结果。